Neuromuscular Update I

Total Page:16

File Type:pdf, Size:1020Kb

Neuromuscular Update I Neuromuscular Update I Gil I. Wolfe, MD Donald B. Sanders, MD James W. Teener, MD Richard A. Lewis, MD Robert T. Leshner, MD Craig M. McDonald, MD David S. Saperstein, MD Neeraj Kumar, MD James K. Richardson, MD 2008 Neuromuscular Update Course C AANEM 55th Annual Meeting Providence, Rhode Island Copyright © September 2008 American Association of Neuromuscular & Electrodiagnostic Medicine 2621 Superior Drive NW Rochester, MN 55901 Printed by Johnson Printing Company, Inc. ii Neuromuscular Update I Faculty Gil I. Wolfe, MD Donald B. Sanders, MD Professor Director Department of Neurology Division of Neurology University of Texas Southwestern Medical School Duke University Medical Center Dallas, Texas Durham, North Carolina Dr. Wolfe is a professor of neurology at the University of Texas (UT) Dr. Sanders received his degree in medicine from Harvard Medical Southwestern Medical School in Dallas, Texas. In September 2004, he was School and trained in neurology at the University of Virginia. He is named to the Dr. Bob and Jean Smith Foundation Distinguished Chair in Professor of Medicine in the Division of Neurology at Duke University Neuromuscular Disease Research. He serves as Co director of the Muscular Medical Center. He founded the Duke EMG Laboratory, where he is the Dystrophy Association Clinics and Director of the Peripheral Neuropathy Co director, and is Director of the Duke Myasthenia Gravis Clinic. He Clinic at UT Southwestern. He is also the Medical Director and acting Vice is the author of many papers on the diagnosis and treatment of neuro- Chair for the department. Dr. Wolfe completed his undergraduate studies muscular diseases, and in 1999 he received the AANEM’s Distinguished at Princeton University and attended medical school at UT Southwestern. Researcher Award. Dr. Sanders is a past-president of the AANEM and has He completed an internal medicine internship and trained as a neurology served on the AANEM’s Workshop, Regional Workshop, and Program resident and neuromuscular/electromyography fellow at the University of Committees, among numerous others. He has also been a board member Pennsylvania Medical Center in Philadelphia. His main research interests of the American Board of Electrodiagnostic Medicine. include idiopathic and immune-mediated peripheral neuropathies and myasthenia gravis. Dr. Wolfe has received the Trephined Cranium Award for excellence in residency teaching on several occasions. He also serves on the medical advisory boards for the Myasthenia Gravis Foundation of America, Charcot-Marie-Tooth Association, and Neuropathy Association, and has been elected Fellow of the American Academy of Neurology and a member in the American Neurological Association. He is certified by the American Board of Psychiatry and Neurology both in neurology and in clinical neurophysiology. James W. Teener, MD Director Neuromuscular Program Department of Neurology University of Michigan Health System Ann Arbor, Michigan Dr. Teener is Director of the Neuromuscular Program, Co director of the EMG Laboratory, and Associate Professor at the University of Michigan. He completed his residency in neurology and a neuromuscular fellowship at the University of Pennsylvania. His research interests include neuro- muscular disorders associated with critical illness and intensive care treat- ment of severe neuromuscular disease. His clinical interests include the full spectrum of neuromuscular disease. He collaborates widely and provides electrodiagnostic expertise to a wide variety of research projects. Authors had nothing to disclose. Course Chair: Gil I. Wolfe, MD The ideas and opinions expressed in this publication are solely those of the specific authors and do not necessarily represent those of the AANEM. iii Richard A. Lewis, MD Robert T. Leshner, MD Professor and Associate Chair Professor Department of Neurology Department of Neurology Wayne State University School of Medicine George Washington University School of Medicine and Health Sciences Detroit, Michigan Washington, DC Dr. Lewis is Professor and Associate Chair of Neurology and Dr. Leshner attended Cornell University for his undergraduate and Co director of the Neuromuscular Program at Wayne State University medical studies. Postgraduate work in internal medicine and pediatrics School of Medicine. He is also Director of the Clinical Neurophysiology were performed at the University of Vermont. A fellowship in adult and Laboratory. He trained in neurology at the University of Pennsylvania and child neurology was completed at the University of Colorado. Following remained on the faculty there before taking positions at the University of several years of active duty as a Navy neurologist, Dr. Leshner performed Connecticut and Eastern Virginia Medical School. Dr. Lewis has been a fellowship training in neuromuscular diseases and electrodiagnostic member of the AANEM since 1979 and has been on a number of com- medicine at the Medical College of Georgia under the watchful eye of mittees including the Examination and Education Committees. He has Dr. Thomas Swift. For over 30 years, his main clinical interest has been been a participant in practice parameter committees on conduction block, the diagnosis and treatment of neuromuscular disorders. Dr. Leshner is multifocal motor neuropathy, and peripheral neuropathy. He is Deputy currently a staff neurologist at the Children’s National Medical Center Editor of the Journal of the Neurological Society and on multiple other in Washington, DC. He holds the rank of Professor of Neurology and editorial boards including Muscle & Nerve. He is on the national and in- Pediatrics at the George Washington University School of Medicine and ternational Medical Advisory Boards of the Myasthenia Gravis Association Health Sciences. Dr. Leshner is also the 2008 recipient of the AANEM’s and Guillain-Barre Syndrome/Chronic Inflammatory Demyelinating Distinguished Researcher Award. His research interests involve trans- Polyneuropathy Foundation International. Dr. Lewis’ interests include the lational research in genetic pediatric neuromuscular diseases. He is the clinical and electrophysiologic aspects of the demyelinating neuropathies, proud father of five children and spends most of his free time spoiling his both acquired and inherited. He is probably best known for his paper five (and counting) grandchildren. on multifocal demyelinating neuropathy, a disorder that is now known as “Lewis-Sumner Syndrome.” Craig M. McDonald, MD Professor Departments of Physical Medicine and Rehabilitation and Pediatrics University of California Davis School of Medicine Davis, California Dr. McDonald is Professor of Physical Medicine and Rehabilitation and Pediatrics and Director of the Neuromuscular Disease Clinics at the University of California (UC) Davis Medical Center. He is Director of the National Institute on Disability and Rehabilitation Research’s Rehabilitation Research and Training Center in Neuromuscular Diseases at UC Davis. His research interests include clinical endpoints in muscular dystrophy, exercise in neuromuscular disease, energy expenditure, quanti- tative assessment of physical activity, and quality-of-life assessment. iv David S. Saperstein, MD Neeraj Kumar, MD Private Practice Associate Professor Phoenix Neurological Associates Department of Neurology Phoenix, Arizona Mayo Clinic Dr. Saperstein practices in Phoenix, Arizona at Phoenix Neurological Rochester, Minnesota Associates, is Co director of the Neuropathy Clinic at Banner Good Dr. Kumar received his medical degree from Maulana Azad Medical Samaritan Regional Medical Center, and is a clinical associate professor of College at the University of Delhi, India and subsequently did a residency neurology at the University of Arizona College of Medicine. Dr. Saperstein in internal medicine and neurology in India. He later completed a resi- received a bachelor’s degree in Biology from Boston University. He com- dency in internal medicine at East Tennessee University and a residency in pleted his medical training at the Boston University School of Medicine, neurology at the University of Minnesota. Dr. Kumar is board-certified performed a neurology residency at Wilford Hall USAF Medical Center in neurology, internal medicine, and electrodiagnostic medicine. He has in San Antonio, Texas, and completed a neuromuscular disease/clini- received the Distinguished Teaching Award from the Minnesota Medical cal neurophysiology fellowship at the University of Texas Southwestern Foundations in 1997 and in 2005 was named Teacher of the Year by the Medical Center in Dallas. Dr. Saperstein is board certified by the American Mayo Fellows Association. His current research interests include diseases Board of Psychiatry and Neurology (with added qualifications in clinical of the spinal cord, disorders of copper metabolism, and neurological ill- neurophysiology) and the American Board of Electrodiagnostic Medicine. nesses related to heavy metals. Dr. Saperstein has a particular interest in the diagnosis, classification and management of peripheral neuropathies, with a focus on immune-medi- ated polyneuropathies and vitamin B12 deficiency neuropathy. James K. Richardson, MD Associate Professor Department of Physical Medicine and Rehabilitation University of Michigan Ann Arbor, Michigan Dr. Richardson graduated from medical school at the University of Cincinnati. He is currently an Associate Professor within the Department of Physical Medicine and Rehabilitation at the University of Michigan. He is board certified
Recommended publications
  • Iron Dysregulation in Movement Disorders
    Neurobiology of Disease 46 (2012) 1–18 Contents lists available at SciVerse ScienceDirect Neurobiology of Disease journal homepage: www.elsevier.com/locate/ynbdi Review Iron dysregulation in movement disorders Petr Dusek a,c, Joseph Jankovic a,⁎, Weidong Le b a Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA b Parkinson's Disease Research Laboratory, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA c Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic article info abstract Article history: Iron is an essential element necessary for energy production, DNA and neurotransmitter synthesis, myelination Received 9 November 2011 and phospholipid metabolism. Neurodegeneration with brain iron accumulation (NBIA) involves several genetic Revised 22 December 2011 disorders, two of which, aceruloplasminemia and neuroferritinopathy, are caused by mutations in genes directly Accepted 31 December 2011 involved in iron metabolic pathway, and others, such as pantothenate-kinase 2, phospholipase-A2 and fatty acid Available online 12 January 2012 2-hydroxylase associated neurodegeneration, are caused by mutations in genes coding for proteins involved in phospholipid metabolism. Phospholipids are major constituents of myelin and iron accumulation has been linked Keywords: Iron to myelin derangements. Another group of NBIAs is caused by mutations in lysosomal enzymes or transporters Neurodegeneration such as ATP13A2, mucolipin-1 and possibly also β-galactosidase and α-fucosidase. Increased cellular iron uptake Dystonia in these diseases may be caused by impaired recycling of iron which normally involves lysosomes.
    [Show full text]
  • Total Serum Phosphate Levels Less Than 3.0 Mg/Dl. • Mild Hypophosp
    HYPOPHOSPHATEMIA DEFINITION: Total serum phosphate levels less than 3.0 mg/dL. Mild hypophosphatemia: 2.5-3.0 mg/dL. Moderate hypophosphatemia: 1.0-2.5 mg/dL. Severe hypophosphatemia: < 1.0 mg/dL. INCIDENCE IN CRITICAL ILLNESS: Common. ETIOLOGY: Transcellular shift: Refeeding syndrome (abrupt initiation of carbohydrate causes an insulin spike, which increases cellular phosphate uptake); exogenous administration of insulin; respiratory alkalosis. Renal loss: Diuretics; osmotic diuresis in diabetic ketoacidosis; hyperparathyroidism (primary and secondary; decreases urinary resorption of phosphate); proximal renal tubular dysfunction (Fanconi’s syndrome). Insufficient intestinal absorption: Malnutrition; phosphate-binding antacids; vitamin D deficiency; chronic diarrhea; nasogastric tube suction; malabsorption. Extreme catabolic states: Burns; trauma; sepsis. CLINICAL MANIFESTATIONS: Cardiovascular: Acute left ventricular dysfunction; reversible dilated cardiomyopathy. Hematologic: Acute hemolytic anemia; leukocyte dysfunction. Neuromuscular: Diffuse skeletal muscle weakness; rhabdomyolysis; bone demineralization; acute and chronic respiratory failure secondary to diaphragmatic weakness (impaired ventilator weaning); confusion and lethargy; gait disturbance; paresthesias. TREATMENT: It is impossible to accurately predict the exact quantity of phosphate repletion required because most phosphate is intracellular. Moderate hypophosphatemia: Oral supplementation is usually adequate (provided the gastrointestinal tract is functional).
    [Show full text]
  • HEMOLYTIC ANEMIA in DISORDERS of REO CELL METABOLISM TOPICS in HEMATOLOGY Series Editor: Maxwell M
    HEMOLYTIC ANEMIA IN DISORDERS OF REO CELL METABOLISM TOPICS IN HEMATOLOGY Series Editor: Maxwell M. Wintrobe, M.D. University of Utah, Salt Lake City THE RESPIRATORY FUNCTIONS OF BLOOD Lars Garby, M.D. and Jerry Meldon, M.D. HEMOLYTIC ANEMIA IN DISORDERS OF RED CELL METABOLISM Ernest Beutler, MD. TRACE ELEMENTS AND IRON IN HUMAN METABOLISM Ananda S. Prasad, M.D. HEMOLYTIC ANEMIA IN DISORDERS OF REO CELL METABOLISM Ernest Beutler, M. O. City of Hope National Medical Center Duarte, California PLENUM MEDICAL BOOK COMPANY· New York and London Library of Congress Cataloging in Publication Data Beutler, Ernest. Hemolytic anemia in disorders of red cell metabolism. (Topics in hematology) Includes index. 1. Hemolytic anemia. 2. Erythrocyte disorders. I. Title. II. Series. CR641.7.H4B48 616.1'52 78-2391 ISBN 978-1-4684-2459-1 ISBN 978-1-4684-2457-7 (eBook) DOI 10.1007/978-1-4684-2457-7 © 1978 Plenum Publishing Corporation Softcover reprint of the hardcover 1st edition 1978 227 West 17th Street, New York, N.Y. 10011 Plenum Medical Book Company is an imprint of Plenum Publishing Corporation All rights reserved No part of this book may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher FOREWORD I am prepared to predict that this monograph by Dr. Ernest Beutler will long serve as a model for monographs dealing with topics in medical science. I make this bold statement because we encounter in this work a degree of accuracy and authoritativeness well beyond that found in much of the medical literature.
    [Show full text]
  • Treatment of Autonomic Dysreflexia for Adults & Adolescents with Spinal
    Treatment of Autonomic Dysreflexia for Adults & Adolescents with Spinal Cord Injuries Authors: Dr James Middleton, Director, State Spinal Cord Injury Service, NSW Agency for Clinical Innovation. Dr Kumaran Ramakrishnan, Honorary Fellow, Rehabilitation Studies Unit, Sydney Medical School Northern, The University of Sydney, and Consultant Rehabilitation Physician & Senior Lecturer, Department of Rehabilitation Medicine, University Malaya. Dr Ian Cameron, Head of the Rehabilitation Studies Unit, Sydney Medical School Northern, The University of Sydney. Reviewed and updated in 2013 by the authors. AGENCY FOR CLINICAL INNOVATION Level 4, Sage Building 67 Albert Avenue Chatswood NSW 2067 PO Box 699 Chatswood NSW 2057 T +61 2 9464 4666 | F +61 2 9464 4728 E [email protected] | www.aci.health.nsw.gov.au Produced by the NSW State Spinal Cord Injury Service. SHPN: (ACI) 140038 ISBN: 978-1-74187-972-8 Further copies of this publication can be obtained from the Agency for Clinical Innovation website at: www.aci.health.nsw.gov.au Disclaimer: Content within this publication was accurate at the time of publication. This work is copyright. It may be reproduced in whole or part for study or training purposes subject to the inclusion of an acknowledgment of the source. It may not be reproduced for commercial usage or sale. Reproduction for purposes other than those indicated above, requires written permission from the Agency for Clinical Innovation. © Agency for Clinical Innovation 2014 Published: February 2014 HS13-136 ACKNOWLEDGEMENTS This document was originally published as a fact sheet for the Rural Spinal Cord Injury Project (RSCIP), a pilot healthcare program for people with a spinal cord injury (SCI) conducted within New South Wales involving the collaboration of Prince Henry & Prince of Wales Hospitals, Royal North Shore Hospital, Royal Rehabilitation Centre Sydney, Spinal Cord Injuries Australia and the Paraplegic & Quadriplegic Association of NSW.
    [Show full text]
  • Scienti®C Review Spastic Movement Disorder
    Spinal Cord (2000) 38, 389 ± 393 ã 2000 International Medical Society of Paraplegia All rights reserved 1362 ± 4393/00 $15.00 www.nature.com/sc Scienti®c Review Spastic movement disorder V Dietz*,1 1Paracare, Paraplegic Centre of the University Hospital Balgrist, ZuÈrich, Switzerland This review deals with the neuronal mechanisms underlying spastic movement disorder, assessed by electrophysiological means with the aim of ®rst, a better understanding of the underlying pathophysiology and second, the selection of an adequate treatment. For the patient usually one of the ®rst symptoms of a lesion within the central motor system represents the movement disorder, which is most characteristic during locomotion in patients with spasticity. The clinical examination reveals exaggerated tendon tap re¯exes and increased muscle tone typical of the spastic movement disorder. However, today we know that there exists only a weak relationship between the physical signs obtained during the clinical examination in a passive motor condition and the impaired neuronal mechanisms being in operation during an active movement. By the recording and analysis of electrophysiological and biomechanical parameters during a functional movement such as locomotion, the signi®cance of, for example, impaired re¯ex behaviour or pathophysiology of muscle tone and its contribution to the movement disorder can reliably be assessed. Consequently, an adequate treatment should not be restricted to the cosmetic therapy and correction of an isolated clinical parameter but should be based on the pathophysiology and signi®cance of the mechanisms underlying the disorder of functional movement which impairs the patient. Spinal Cord (2000) 38, 389 ± 393 Keywords: spinal cord injury; spasticity; electrophysiological recordings; treatment Introduction Movement disorders are prominent features of impaired strength of electromyographic (EMG) activation of function of the motor systems and are frequently best antagonistic leg muscles as well as intrinsic and passive re¯ected during gait.
    [Show full text]
  • Veterinary Toxicology
    GINTARAS DAUNORAS VETERINARY TOXICOLOGY Lecture notes and classes works Study kit for LUHS Veterinary Faculty Foreign Students LSMU LEIDYBOS NAMAI, KAUNAS 2012 Lietuvos sveikatos moksl ų universitetas Veterinarijos akademija Neužkre čiam ųjų lig ų katedra Gintaras Daunoras VETERINARIN Ė TOKSIKOLOGIJA Paskait ų konspektai ir praktikos darb ų aprašai Mokomoji knyga LSMU Veterinarijos fakulteto užsienio studentams LSMU LEIDYBOS NAMAI, KAUNAS 2012 UDK Dau Apsvarstyta: LSMU VA Veterinarijos fakulteto Neužkre čiam ųjų lig ų katedros pos ėdyje, 2012 m. rugs ėjo 20 d., protokolo Nr. 01 LSMU VA Veterinarijos fakulteto tarybos pos ėdyje, 2012 m. rugs ėjo 28 d., protokolo Nr. 08 Recenzavo: doc. dr. Alius Pockevi čius LSMU VA Užkre čiam ųjų lig ų katedra dr. Aidas Grigonis LSMU VA Neužkre čiam ųjų lig ų katedra CONTENTS Introduction ……………………………………………………………………………………… 7 SECTION I. Lecture notes ………………………………………………………………………. 8 1. GENERAL VETERINARY TOXICOLOGY ……….……………………………………….. 8 1.1. Veterinary toxicology aims and tasks ……………………………………………………... 8 1.2. EC and Lithuanian legal documents for hazardous substances and pollution ……………. 11 1.3. Classification of poisons ……………………………………………………………………. 12 1.4. Chemicals classification and labelling ……………………………………………………… 14 2. Toxicokinetics ………………………………………………………………………...………. 15 2.2. Migration of substances through biological membranes …………………………………… 15 2.3. ADME notion ………………………………………………………………………………. 15 2.4. Possibilities of poisons entering into an animal body and methods of absorption ……… 16 2.5. Poison distribution
    [Show full text]
  • Randomized Trial of Intravenous Iron-Induced Hypophosphatemia
    CLINICAL MEDICINE Randomized trial of intravenous iron-induced hypophosphatemia Myles Wolf,1,2 Glenn M. Chertow,3,4 Iain C. Macdougall,5 Robert Kaper,6 Julie Krop,6 and William Strauss6 1Division of Nephrology, Department of Medicine, and 2Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA. 3Division of Nephrology, Department of Medicine and 4Department of Health Research and Policy, Stanford University, Stanford, California, USA. 5Renal Unit, King’s College Hospital, London, United Kingdom. 6AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, USA. BACKGROUND. Hypophosphatemia can complicate intravenous iron therapy, but no head-to-head trials compared the effects of newer intravenous iron formulations on risks and mediators of hypophosphatemia. METHODS. In a randomized, double-blinded, controlled trial of adults with iron deficiency anemia from February 2016 to January 2017, we compared rates of hypophosphatemia in response to a single FDA-approved course of ferric carboxymaltose (n = 1,000) or ferumoxytol (n = 997). To investigate pathophysiological mediators of intravenous iron-induced hypophosphatemia, we nested within the parent trial a physiological substudy (ferric carboxymaltose, n = 98; ferumoxytol, n = 87) in which we measured fibroblast growth factor 23 (FGF23), calcitriol, and parathyroid hormone (PTH) at baseline and 1, 2, and 5 weeks later. RESULTS. The incidence of hypophosphatemia was significantly higher in the ferric carboxymaltose versus the ferumoxytol group (<2.0 mg/dl, 50.8% vs. 0.9%; <1.3 mg/dl, 10.0% vs. 0.0%; P < 0.001), and hypophosphatemia persisted through the end of the 5-week study period in 29.1% of ferric carboxymaltose–treated patients versus none of the ferumoxytol-treated patients (P < 0.001).
    [Show full text]
  • Neuromuscular Disorders Neurology in Practice: Series Editors: Robert A
    Neuromuscular Disorders neurology in practice: series editors: robert a. gross, department of neurology, university of rochester medical center, rochester, ny, usa jonathan w. mink, department of neurology, university of rochester medical center,rochester, ny, usa Neuromuscular Disorders edited by Rabi N. Tawil, MD Professor of Neurology University of Rochester Medical Center Rochester, NY, USA Shannon Venance, MD, PhD, FRCPCP Associate Professor of Neurology The University of Western Ontario London, Ontario, Canada A John Wiley & Sons, Ltd., Publication This edition fi rst published 2011, ® 2011 by Blackwell Publishing Ltd Blackwell Publishing was acquired by John Wiley & Sons in February 2007. Blackwell’s publishing program has been merged with Wiley’s global Scientifi c, Technical and Medical business to form Wiley-Blackwell. Registered offi ce: John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK Editorial offi ces: 9600 Garsington Road, Oxford, OX4 2DQ, UK The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK 111 River Street, Hoboken, NJ 07030-5774, USA For details of our global editorial offi ces, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell The right of the author to be identifi ed as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.
    [Show full text]
  • Non-Progressive Congenital Ataxia with Cerebellar Hypoplasia in Three Families
    248 Non-progressive congenital ataxia with cerebellar hypoplasia in three families . No 1.6 Z. YAPICI & M. ERAKSOY . .. I.Y.. \ .~ ---················ No of Neurology, of Child Neuro/ogy, Facu/ty of Turkey Abstract Non-progressive with cerebellar hypoplasia are a rarely seen heterogeneous group ofhereditary cerebellar ataxias. Three sib pairs from three different families with this entity have been reviewed, and differential diagnosis has been di sc ussed. in two of the families, the parents were consanguineous. Walking was delayed in ali the children. Truncal and extremiry were then noticed. Ataxia was severe in one child, moderate in two children, and mild in the remaining revealed horizontal, horizonto-rotatory and/or vertical variable degrees ofmental and pvramidal signs besides truncal and extremity ataxia. In ali the cases, cerebellar hemisphere and vermis were in MRI . During the follow-up period, a gradual clinical improvement was achieved in ali the Condusion: he cu nsidered as recessive in some of the non-progressive ataxic syndromes. are being due to the rarity oflarge pedigrees for genetic studies. Iffurther on and clini cal progression of childhood associated with cerebellar hypoplasia is be a cu mbined of metabolic screening, long-term follow-up and radiological analyses is essential. Key Words: Cerebella r hy poplasia, ataxic syndromes are common during Patients 1 and 2 (first family) childhood. Friedreich 's ataxia and ataxia-telangiectasia Two brothers aged 5 and 7 of unrelated parents arc two best-known examples of such rare syn- presented with a history of slurred speech and diffi- dromes characterized both by their progressive nature culty of gait.
    [Show full text]
  • The Hematological Complications of Alcoholism
    The Hematological Complications of Alcoholism HAROLD S. BALLARD, M.D. Alcohol has numerous adverse effects on the various types of blood cells and their functions. For example, heavy alcohol consumption can cause generalized suppression of blood cell production and the production of structurally abnormal blood cell precursors that cannot mature into functional cells. Alcoholics frequently have defective red blood cells that are destroyed prematurely, possibly resulting in anemia. Alcohol also interferes with the production and function of white blood cells, especially those that defend the body against invading bacteria. Consequently, alcoholics frequently suffer from bacterial infections. Finally, alcohol adversely affects the platelets and other components of the blood-clotting system. Heavy alcohol consumption thus may increase the drinker’s risk of suffering a stroke. KEY WORDS: adverse drug effect; AODE (alcohol and other drug effects); blood function; cell growth and differentiation; erythrocytes; leukocytes; platelets; plasma proteins; bone marrow; anemia; blood coagulation; thrombocytopenia; fibrinolysis; macrophage; monocyte; stroke; bacterial disease; literature review eople who abuse alcohol1 are at both direct and indirect. The direct in the number and function of WBC’s risk for numerous alcohol-related consequences of excessive alcohol increases the drinker’s risk of serious Pmedical complications, includ- consumption include toxic effects on infection, and impaired platelet produc- ing those affecting the blood (i.e., the the bone marrow; the blood cell pre- tion and function interfere with blood cursors; and the mature red blood blood cells as well as proteins present clotting, leading to symptoms ranging in the blood plasma) and the bone cells (RBC’s), white blood cells from a simple nosebleed to bleeding in marrow, where the blood cells are (WBC’s), and platelets.
    [Show full text]
  • Secondary Hemochromatosis As a Result of Acute Transfusion-Induced Iron Overload in a Burn Patient Michael Amatto1 and Hernish Acharya2*
    Amatto and Acharya Burns & Trauma (2016) 4:10 DOI 10.1186/s41038-016-0034-z CASE REPORT Open Access Secondary hemochromatosis as a result of acute transfusion-induced iron overload in a burn patient Michael Amatto1 and Hernish Acharya2* Abstract Background: Red blood cell transfusions are critical in burn management. The subsequent iron overload that can occur from this treatment can lead to secondary hemochromatosis with multi-organ damage. Case Presentation: While well recognized in patients receiving chronic transfusions, we present a case outlining the acute development of hemochromatosis secondary to multiple transfusions in a burn patient. Conclusions: Simple screening laboratory measures and treatment options exist which may significantly reduce morbidity; thus, we believe awareness of secondary hemochromatosis in those treating burn patients is critical. Keywords: Secondary hemochromatosis, Transfusion, Iron overload, Burn patients Background of parental iron or RBC transfusions, neonatal iron over- Acute and chronic treatment of the severely burned indi- load, aceruloplasminemia, and African iron overload [6, 7]. vidual is often complex due to many physical and psycho- Hemochromatosis is a disease characterized by iron logical factors [1, 2]. Resuscitation involving packed red accumulation in tissues. Initial symptoms and signs in- blood cell (RBC) transfusion is often essential [3]. How- clude skin pigmentation, fatigue, erectile dysfunction, ever, RBC transfusion carries potential risks including and arthralgia while later stages of the disease result in hemolytic reactions and infections, as well as other com- cardiomyopathy, diabetes mellitus, hypogonadism, hypo- plications that are often overlooked such as iron overload pituitarism, and hypoparathyroidism, as well as liver fi- [4, 5]. Each unit of RBCs contains 200–250 mg of iron, brosis and cirrhosis which can lead to hepatocellular and with no physiologic excretion mechanism, multiple carcinoma [6].
    [Show full text]
  • Technical Guidance for the Classification of Copper Metal Under the Globally Harmonized System for Classification and Labelling of Chemicals (GHS)
    Technical Guidance for the Classification of Copper Metal Under the Globally Harmonized System for Classification and Labelling of Chemicals (GHS) Prepared with International Copper Association (ICA) January 21, 2020 Table of Contents Page Executive Summary .................................................................................................................... ES-1 1 Introduction and Scope ....................................................................................................... 1 2 Physical Hazard Classifications............................................................................................ 5 2.1 Summary of Physical Hazard Classifications ........................................................... 6 2.2 Combustible Dust Considerations for Copper Metal .............................................. 7 2.2.1 Dust Particle Size ......................................................................................... 8 3 GHS Human Health Hazard Classifications ......................................................................... 9 3.1 Copper Massive ..................................................................................................... 11 3.2 Copper Powder ..................................................................................................... 15 3.3 Coated Copper Flakes ........................................................................................... 21 3.4 Summary of GHS Human Health Hazard Classifications ....................................... 26 4 GHS Environmental
    [Show full text]